Transplant-associated autoimmune mechanisms in human hepatitis C virus infection

Keith Zucker, David Roth, Robert Cirocco, James Mathew, Manuel Carreno, Laphalle Fuller, Theodore Karatzas, Yide Jin, George W Burke, Jose Nery, Marc Webb, Andreas Tzakis, Violet Esquenazi, Joshua Miller

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In order to define factors which are important for the development of hepatitis C virus (HCV) infection and disease in transplant patients, we examined the role of class II MHC antigen restriction in viral antigen presentation to support a hypothesis of the association of this disease with an autoimmune pathogenesis. A greater degree of histocompatibility match between these donors and their HCV-negative recipients was associated with a greater predisposition to recipient HCV liver disease (ALT elevation) posttransplant. The HCV carrier state could be identified with significant amplification of autologous mixed lymphocyte reactivity (AMLR) in both long-term hemodialysis and long-term renal transplant patients, but the AMLR was absent in end-stage liver disease patients with HCV-associated cirrhosis and was insignificantly elevated in these patients with persistent infection in the first 2 years after a new liver was transplanted. There was also a moderate reduction in autologous reactivity as well as serum HCV titers among renal transplant patients who displayed biochemical evidence of chronic liver disease as opposed to those who did not. This appeared later in the course of the disease. HCV RNA could be detected in peripheral blood mononuclear cells (PBMC) of only a portion of HCV-infected renal transplant patients and these showed significantly higher autologous reactivity. In contrast, despite the fact that observations were earlier after de novo liver transplantation, HCV RNA (i.e., earlier in the course of a new or recurrent disease process) was found in PBMC of all liver transplant recipients tested. The AMLR of noninfected laboratory volunteers could be amplified by preincubating their stimulating cells (APCs) with enriched HCV possibly in immune complex (pHCV-IC). This amplification appeared only with specific combinations of HCV strains with HLA DR serotypes. In addition, HCV-primed T cells could be generated to the virus which displayed accelerated activation kinetics. Liver infiltrating lymphocytes extracted from HCV-positive end-stage diseased livers had significantly higher proliferative and cytotoxic reactivity to autologous (HCV-infected) hepatocytes than the extracted lymphocytes responding to autologous hepatocytes from HCV-negative livers. These findings offer evidence of dynamic autoimmune mechanisms in the spectrum of progression of HCV disease and may help to predict the effect of intervention at various intervals in this progression in organ transplant recipients.

Original languageEnglish
Pages (from-to)60-70
Number of pages11
JournalJournal of Clinical Immunology
Volume16
Issue number1
DOIs
StatePublished - Feb 6 1996

Fingerprint

Virus Diseases
Hepacivirus
Transplants
Lymphocytes
End Stage Liver Disease
Liver
Kidney
Liver Diseases
Hepatocytes
Blood Cells
RNA
Carrier State
Histocompatibility
Viral Antigens
Histocompatibility Antigens Class II
Autografts
Antigen Presentation
HLA-DR Antigens
Antigen-Antibody Complex
Viral Load

Keywords

  • Autoimmune disease
  • Hepatitis C virus
  • Histocompatibility antigens
  • Non-A, non-B hepatitis
  • Renal transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Zucker, K., Roth, D., Cirocco, R., Mathew, J., Carreno, M., Fuller, L., ... Miller, J. (1996). Transplant-associated autoimmune mechanisms in human hepatitis C virus infection. Journal of Clinical Immunology, 16(1), 60-70. https://doi.org/10.1007/BF01540974

Transplant-associated autoimmune mechanisms in human hepatitis C virus infection. / Zucker, Keith; Roth, David; Cirocco, Robert; Mathew, James; Carreno, Manuel; Fuller, Laphalle; Karatzas, Theodore; Jin, Yide; Burke, George W; Nery, Jose; Webb, Marc; Tzakis, Andreas; Esquenazi, Violet; Miller, Joshua.

In: Journal of Clinical Immunology, Vol. 16, No. 1, 06.02.1996, p. 60-70.

Research output: Contribution to journalArticle

Zucker, K, Roth, D, Cirocco, R, Mathew, J, Carreno, M, Fuller, L, Karatzas, T, Jin, Y, Burke, GW, Nery, J, Webb, M, Tzakis, A, Esquenazi, V & Miller, J 1996, 'Transplant-associated autoimmune mechanisms in human hepatitis C virus infection', Journal of Clinical Immunology, vol. 16, no. 1, pp. 60-70. https://doi.org/10.1007/BF01540974
Zucker, Keith ; Roth, David ; Cirocco, Robert ; Mathew, James ; Carreno, Manuel ; Fuller, Laphalle ; Karatzas, Theodore ; Jin, Yide ; Burke, George W ; Nery, Jose ; Webb, Marc ; Tzakis, Andreas ; Esquenazi, Violet ; Miller, Joshua. / Transplant-associated autoimmune mechanisms in human hepatitis C virus infection. In: Journal of Clinical Immunology. 1996 ; Vol. 16, No. 1. pp. 60-70.
@article{4ed4e2b01c484f729fd163170673745a,
title = "Transplant-associated autoimmune mechanisms in human hepatitis C virus infection",
abstract = "In order to define factors which are important for the development of hepatitis C virus (HCV) infection and disease in transplant patients, we examined the role of class II MHC antigen restriction in viral antigen presentation to support a hypothesis of the association of this disease with an autoimmune pathogenesis. A greater degree of histocompatibility match between these donors and their HCV-negative recipients was associated with a greater predisposition to recipient HCV liver disease (ALT elevation) posttransplant. The HCV carrier state could be identified with significant amplification of autologous mixed lymphocyte reactivity (AMLR) in both long-term hemodialysis and long-term renal transplant patients, but the AMLR was absent in end-stage liver disease patients with HCV-associated cirrhosis and was insignificantly elevated in these patients with persistent infection in the first 2 years after a new liver was transplanted. There was also a moderate reduction in autologous reactivity as well as serum HCV titers among renal transplant patients who displayed biochemical evidence of chronic liver disease as opposed to those who did not. This appeared later in the course of the disease. HCV RNA could be detected in peripheral blood mononuclear cells (PBMC) of only a portion of HCV-infected renal transplant patients and these showed significantly higher autologous reactivity. In contrast, despite the fact that observations were earlier after de novo liver transplantation, HCV RNA (i.e., earlier in the course of a new or recurrent disease process) was found in PBMC of all liver transplant recipients tested. The AMLR of noninfected laboratory volunteers could be amplified by preincubating their stimulating cells (APCs) with enriched HCV possibly in immune complex (pHCV-IC). This amplification appeared only with specific combinations of HCV strains with HLA DR serotypes. In addition, HCV-primed T cells could be generated to the virus which displayed accelerated activation kinetics. Liver infiltrating lymphocytes extracted from HCV-positive end-stage diseased livers had significantly higher proliferative and cytotoxic reactivity to autologous (HCV-infected) hepatocytes than the extracted lymphocytes responding to autologous hepatocytes from HCV-negative livers. These findings offer evidence of dynamic autoimmune mechanisms in the spectrum of progression of HCV disease and may help to predict the effect of intervention at various intervals in this progression in organ transplant recipients.",
keywords = "Autoimmune disease, Hepatitis C virus, Histocompatibility antigens, Non-A, non-B hepatitis, Renal transplantation",
author = "Keith Zucker and David Roth and Robert Cirocco and James Mathew and Manuel Carreno and Laphalle Fuller and Theodore Karatzas and Yide Jin and Burke, {George W} and Jose Nery and Marc Webb and Andreas Tzakis and Violet Esquenazi and Joshua Miller",
year = "1996",
month = "2",
day = "6",
doi = "10.1007/BF01540974",
language = "English",
volume = "16",
pages = "60--70",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Transplant-associated autoimmune mechanisms in human hepatitis C virus infection

AU - Zucker, Keith

AU - Roth, David

AU - Cirocco, Robert

AU - Mathew, James

AU - Carreno, Manuel

AU - Fuller, Laphalle

AU - Karatzas, Theodore

AU - Jin, Yide

AU - Burke, George W

AU - Nery, Jose

AU - Webb, Marc

AU - Tzakis, Andreas

AU - Esquenazi, Violet

AU - Miller, Joshua

PY - 1996/2/6

Y1 - 1996/2/6

N2 - In order to define factors which are important for the development of hepatitis C virus (HCV) infection and disease in transplant patients, we examined the role of class II MHC antigen restriction in viral antigen presentation to support a hypothesis of the association of this disease with an autoimmune pathogenesis. A greater degree of histocompatibility match between these donors and their HCV-negative recipients was associated with a greater predisposition to recipient HCV liver disease (ALT elevation) posttransplant. The HCV carrier state could be identified with significant amplification of autologous mixed lymphocyte reactivity (AMLR) in both long-term hemodialysis and long-term renal transplant patients, but the AMLR was absent in end-stage liver disease patients with HCV-associated cirrhosis and was insignificantly elevated in these patients with persistent infection in the first 2 years after a new liver was transplanted. There was also a moderate reduction in autologous reactivity as well as serum HCV titers among renal transplant patients who displayed biochemical evidence of chronic liver disease as opposed to those who did not. This appeared later in the course of the disease. HCV RNA could be detected in peripheral blood mononuclear cells (PBMC) of only a portion of HCV-infected renal transplant patients and these showed significantly higher autologous reactivity. In contrast, despite the fact that observations were earlier after de novo liver transplantation, HCV RNA (i.e., earlier in the course of a new or recurrent disease process) was found in PBMC of all liver transplant recipients tested. The AMLR of noninfected laboratory volunteers could be amplified by preincubating their stimulating cells (APCs) with enriched HCV possibly in immune complex (pHCV-IC). This amplification appeared only with specific combinations of HCV strains with HLA DR serotypes. In addition, HCV-primed T cells could be generated to the virus which displayed accelerated activation kinetics. Liver infiltrating lymphocytes extracted from HCV-positive end-stage diseased livers had significantly higher proliferative and cytotoxic reactivity to autologous (HCV-infected) hepatocytes than the extracted lymphocytes responding to autologous hepatocytes from HCV-negative livers. These findings offer evidence of dynamic autoimmune mechanisms in the spectrum of progression of HCV disease and may help to predict the effect of intervention at various intervals in this progression in organ transplant recipients.

AB - In order to define factors which are important for the development of hepatitis C virus (HCV) infection and disease in transplant patients, we examined the role of class II MHC antigen restriction in viral antigen presentation to support a hypothesis of the association of this disease with an autoimmune pathogenesis. A greater degree of histocompatibility match between these donors and their HCV-negative recipients was associated with a greater predisposition to recipient HCV liver disease (ALT elevation) posttransplant. The HCV carrier state could be identified with significant amplification of autologous mixed lymphocyte reactivity (AMLR) in both long-term hemodialysis and long-term renal transplant patients, but the AMLR was absent in end-stage liver disease patients with HCV-associated cirrhosis and was insignificantly elevated in these patients with persistent infection in the first 2 years after a new liver was transplanted. There was also a moderate reduction in autologous reactivity as well as serum HCV titers among renal transplant patients who displayed biochemical evidence of chronic liver disease as opposed to those who did not. This appeared later in the course of the disease. HCV RNA could be detected in peripheral blood mononuclear cells (PBMC) of only a portion of HCV-infected renal transplant patients and these showed significantly higher autologous reactivity. In contrast, despite the fact that observations were earlier after de novo liver transplantation, HCV RNA (i.e., earlier in the course of a new or recurrent disease process) was found in PBMC of all liver transplant recipients tested. The AMLR of noninfected laboratory volunteers could be amplified by preincubating their stimulating cells (APCs) with enriched HCV possibly in immune complex (pHCV-IC). This amplification appeared only with specific combinations of HCV strains with HLA DR serotypes. In addition, HCV-primed T cells could be generated to the virus which displayed accelerated activation kinetics. Liver infiltrating lymphocytes extracted from HCV-positive end-stage diseased livers had significantly higher proliferative and cytotoxic reactivity to autologous (HCV-infected) hepatocytes than the extracted lymphocytes responding to autologous hepatocytes from HCV-negative livers. These findings offer evidence of dynamic autoimmune mechanisms in the spectrum of progression of HCV disease and may help to predict the effect of intervention at various intervals in this progression in organ transplant recipients.

KW - Autoimmune disease

KW - Hepatitis C virus

KW - Histocompatibility antigens

KW - Non-A, non-B hepatitis

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=9044230922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044230922&partnerID=8YFLogxK

U2 - 10.1007/BF01540974

DO - 10.1007/BF01540974

M3 - Article

VL - 16

SP - 60

EP - 70

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 1

ER -